共 229 条
[1]
Williams B(2018)2018 ESC/ESH Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Cardiology (ESC) and the European Society of Hypertension (ESH) Eur Heart J 39 3021-3104
[2]
Mancia G(2011)Medical treatment of benign prostatic hyperplasia Reviews in urology 13 20-33
[3]
Spiering W(2013)EAU guidelines on the treatment and follow-up of non-neurogenic male lower urinary tract symptoms including benign prostatic obstruction Eur Urol 64 118-140
[4]
Agabiti Rosei E(2008)Alpha1-adrenoceptor subtypes and lower urinary tract symptoms International journal of urology : official journal of the Japanese Urological Association 15 193-199
[5]
Azizi M(2010)The forefront for novel therapeutic agents based on the pathophysiology of lower urinary tract dysfunction: alpha-blockers in the treatment of male voiding dysfunction - how do they work and why do they differ in tolerability? J Pharmacol Sci 112 151-157
[6]
Burnier M(2013)Prevalence, Awareness, Treatment, and Control of Hypertension in Rural and Urban Communities in High-, Middle-, and Low-Income Countries JAMA 310 959-968
[7]
Lepor H(2010)Benign Prostatic Hyperplasia and Male Lower Urinary Tract Symptoms: Epidemiology and Risk Factors Current bladder dysfunction reports 5 212-218
[8]
Oelke M(2005)Global burden of hypertension: analysis of worldwide data The Lancet 365 217-223
[9]
Bachmann A(2013)Obesity and benign prostatic hyperplasia: clinical connections, emerging etiological paradigms and future directions J Urol 189 S102-S106
[10]
Descazeaud A(2014)Epidemiology and etiology of benign prostatic hyperplasia and bladder outlet obstruction Indian journal of urology : IJU : journal of the Urological Society of India 30 170-176